Provided by Tiger Trade Technology Pte. Ltd.

ACADIA Pharmaceuticals

19.95
+0.06000.30%
Post-market: 19.950.00000.00%19:30 EDT
Volume:2.56M
Turnover:51.35M
Market Cap:3.44B
PE:9.09
High:20.24
Open:20.01
Low:19.88
Close:19.89
52wk High:30.96
52wk Low:19.59
Shares:172.31M
Float Shares:128.72M
Volume Ratio:0.84
T/O Rate:1.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.20
EPS(LYR):2.30
ROE:35.74%
ROA:3.64%
PB:2.63
PE(LYR):8.67

Loading ...

Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD) and Pennant Group (PNTG)

TIPRANKS
·
Jun 27

Acadia Pharmaceuticals up Nearly 11%, on Track for Largest Percent Increase Since May 2025

Dow Jones
·
Jun 27

Acadia Pharmaceuticals rises 9.9%

TIPRANKS
·
Jun 26

Acadia Pharma Jumps After EU Panel Reverses Opinion on Neurological Disorder Drug

Reuters
·
Jun 26

Daybu® (trofinetide) Recommended for Approval in the European Union by CHMP

Reuters
·
Jun 26

Acadia Pharmaceuticals: Daybu recommended for approval in EU by CHMP

TIPRANKS
·
Jun 26

Acadia’s DAYBU Wins Positive CHMP Opinion for EU Approval in Rett Syndrome

Reuters
·
Jun 26

Daybu® (trofinetide) Recommended for Approval in the European Union by Chmp

THOMSON REUTERS
·
Jun 26

Acadia Pharmaceuticals - European Commission Decision on Daybu Expected in Coming Months

THOMSON REUTERS
·
Jun 26

Acadia Pharmaceuticals - Daybu Marketing Authorization Would Cover EU, Iceland, Liechtenstein, Norway if Approved

THOMSON REUTERS
·
Jun 26

How Investors May Respond To ACADIA Pharmaceuticals (ACAD) ESOP-Linked Shelf Registration And Potential Dilution

Simply Wall St.
·
Jun 19

ACADIA Pharmaceuticals shareholders approved 5.21 million-share increase to 2024 equity plan

Reuters
·
May 30

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cardiff Oncology (CRDF), ACADIA Pharmaceuticals (ACAD) and Immunic (IMUX)

TIPRANKS
·
May 22

Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Pipeline Progress And Product Rollouts

Simply Wall St.
·
May 21

A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Mixed Q1 2026 Results And EU Trofinetide Setback

Simply Wall St.
·
May 11

ACADIA Pharmaceuticals Is Maintained at Buy by Citigroup

Dow Jones
·
May 09

ACADIA Pharmaceuticals Signals Confident Path After Q1 Call

TIPRANKS
·
May 08

Analysts Have Conflicting Sentiments on These Healthcare Companies: Evotec AG (EVO), Vaxcyte (PCVX) and ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
May 08

RBC Capital Sticks to Their Buy Rating for ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
May 07

Analysts Offer Insights on Healthcare Companies: Kissei Pharmaceutical Co (OtherKSPHF), Recursion Pharmaceuticals (RXRX) and ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
May 07